A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer

Chiara Paglino, Giuseppe Procopio, Roberto Sabbatini, Joaquim Bellmunt, Manuela Schmidinger, Alessandra Bearz, Aristotelis Bamias, Bohuslav Melichar, Ilaria Imarisio, Carmine Tinelli, Camillo Porta

Research output: Contribution to journalArticle

Abstract

Background/Aim: the ideal sequence of targeted agents for advanced kidney cancer is still unknown. In the present study we assessed the clinical benefit of two different sequential approaches, namely sorafenib, an inhibitor of mammalian target of rapamycin (mTORi) and sunitinib, or sunitinib (an mTORi) and sorafenib. Patients and Methods: we retrospectively reviewed the outcome of 40 advanced kidney cancer patients treated with one of the two above sequences. Results: a total of 26 patients were treated with the sequence sorafenib-mTORi-sunitinib and 14 with the sequence sunitinib-mTORi-sorafenib. The actuarial overall median progression-free survival (PFS) in the sorafenib-mTORi-sunitinib group and in the sunitinib-mTORi-sorafenib group were 21.9 and 22.8 months, respectively (log-rank test: p=0.928). In the sorafenib-mTORi- sunitinib group, patients in first-, second- and third-line therapy experienced PFS of 11.7, 5.1 and 9.1 months, respectively, while in the sunitinib-mTORi-sorafenib group PFS was 14.4, 4.3, and 3.9 months, respectively. Conclusion: Our results suggest there is no significant difference between the two sequence modalities.

Original languageEnglish
Pages (from-to)4999-5004
Number of pages6
JournalAnticancer Research
Volume33
Issue number11
Publication statusPublished - Nov 2013

Fingerprint

Kidney Neoplasms
Sirolimus
Disease-Free Survival
Therapeutics
sunitinib
sorafenib

Keywords

  • Drug sequence
  • Everolimus
  • Kidney cancer
  • Sorafenib
  • Sunitinib
  • Temisrolimus

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer. / Paglino, Chiara; Procopio, Giuseppe; Sabbatini, Roberto; Bellmunt, Joaquim; Schmidinger, Manuela; Bearz, Alessandra; Bamias, Aristotelis; Melichar, Bohuslav; Imarisio, Ilaria; Tinelli, Carmine; Porta, Camillo.

In: Anticancer Research, Vol. 33, No. 11, 11.2013, p. 4999-5004.

Research output: Contribution to journalArticle

Paglino, Chiara ; Procopio, Giuseppe ; Sabbatini, Roberto ; Bellmunt, Joaquim ; Schmidinger, Manuela ; Bearz, Alessandra ; Bamias, Aristotelis ; Melichar, Bohuslav ; Imarisio, Ilaria ; Tinelli, Carmine ; Porta, Camillo. / A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer. In: Anticancer Research. 2013 ; Vol. 33, No. 11. pp. 4999-5004.
@article{27d04b47089244639ec416813d9b4052,
title = "A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer",
abstract = "Background/Aim: the ideal sequence of targeted agents for advanced kidney cancer is still unknown. In the present study we assessed the clinical benefit of two different sequential approaches, namely sorafenib, an inhibitor of mammalian target of rapamycin (mTORi) and sunitinib, or sunitinib (an mTORi) and sorafenib. Patients and Methods: we retrospectively reviewed the outcome of 40 advanced kidney cancer patients treated with one of the two above sequences. Results: a total of 26 patients were treated with the sequence sorafenib-mTORi-sunitinib and 14 with the sequence sunitinib-mTORi-sorafenib. The actuarial overall median progression-free survival (PFS) in the sorafenib-mTORi-sunitinib group and in the sunitinib-mTORi-sorafenib group were 21.9 and 22.8 months, respectively (log-rank test: p=0.928). In the sorafenib-mTORi- sunitinib group, patients in first-, second- and third-line therapy experienced PFS of 11.7, 5.1 and 9.1 months, respectively, while in the sunitinib-mTORi-sorafenib group PFS was 14.4, 4.3, and 3.9 months, respectively. Conclusion: Our results suggest there is no significant difference between the two sequence modalities.",
keywords = "Drug sequence, Everolimus, Kidney cancer, Sorafenib, Sunitinib, Temisrolimus",
author = "Chiara Paglino and Giuseppe Procopio and Roberto Sabbatini and Joaquim Bellmunt and Manuela Schmidinger and Alessandra Bearz and Aristotelis Bamias and Bohuslav Melichar and Ilaria Imarisio and Carmine Tinelli and Camillo Porta",
year = "2013",
month = "11",
language = "English",
volume = "33",
pages = "4999--5004",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "11",

}

TY - JOUR

T1 - A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer

AU - Paglino, Chiara

AU - Procopio, Giuseppe

AU - Sabbatini, Roberto

AU - Bellmunt, Joaquim

AU - Schmidinger, Manuela

AU - Bearz, Alessandra

AU - Bamias, Aristotelis

AU - Melichar, Bohuslav

AU - Imarisio, Ilaria

AU - Tinelli, Carmine

AU - Porta, Camillo

PY - 2013/11

Y1 - 2013/11

N2 - Background/Aim: the ideal sequence of targeted agents for advanced kidney cancer is still unknown. In the present study we assessed the clinical benefit of two different sequential approaches, namely sorafenib, an inhibitor of mammalian target of rapamycin (mTORi) and sunitinib, or sunitinib (an mTORi) and sorafenib. Patients and Methods: we retrospectively reviewed the outcome of 40 advanced kidney cancer patients treated with one of the two above sequences. Results: a total of 26 patients were treated with the sequence sorafenib-mTORi-sunitinib and 14 with the sequence sunitinib-mTORi-sorafenib. The actuarial overall median progression-free survival (PFS) in the sorafenib-mTORi-sunitinib group and in the sunitinib-mTORi-sorafenib group were 21.9 and 22.8 months, respectively (log-rank test: p=0.928). In the sorafenib-mTORi- sunitinib group, patients in first-, second- and third-line therapy experienced PFS of 11.7, 5.1 and 9.1 months, respectively, while in the sunitinib-mTORi-sorafenib group PFS was 14.4, 4.3, and 3.9 months, respectively. Conclusion: Our results suggest there is no significant difference between the two sequence modalities.

AB - Background/Aim: the ideal sequence of targeted agents for advanced kidney cancer is still unknown. In the present study we assessed the clinical benefit of two different sequential approaches, namely sorafenib, an inhibitor of mammalian target of rapamycin (mTORi) and sunitinib, or sunitinib (an mTORi) and sorafenib. Patients and Methods: we retrospectively reviewed the outcome of 40 advanced kidney cancer patients treated with one of the two above sequences. Results: a total of 26 patients were treated with the sequence sorafenib-mTORi-sunitinib and 14 with the sequence sunitinib-mTORi-sorafenib. The actuarial overall median progression-free survival (PFS) in the sorafenib-mTORi-sunitinib group and in the sunitinib-mTORi-sorafenib group were 21.9 and 22.8 months, respectively (log-rank test: p=0.928). In the sorafenib-mTORi- sunitinib group, patients in first-, second- and third-line therapy experienced PFS of 11.7, 5.1 and 9.1 months, respectively, while in the sunitinib-mTORi-sorafenib group PFS was 14.4, 4.3, and 3.9 months, respectively. Conclusion: Our results suggest there is no significant difference between the two sequence modalities.

KW - Drug sequence

KW - Everolimus

KW - Kidney cancer

KW - Sorafenib

KW - Sunitinib

KW - Temisrolimus

UR - http://www.scopus.com/inward/record.url?scp=84891354637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891354637&partnerID=8YFLogxK

M3 - Article

C2 - 24222142

AN - SCOPUS:84891354637

VL - 33

SP - 4999

EP - 5004

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 11

ER -